132 research outputs found

    Recent Case Law on Maryland\u27s Speedy Trial Rule

    Get PDF

    Recent Case Law on Maryland\u27s Speedy Trial Rule

    Get PDF

    Alien Registration- Comeau, Mary E. (Old Town, Penobscot County)

    Get PDF
    https://digitalmaine.com/alien_docs/7120/thumbnail.jp

    Circular 89

    Get PDF
    A yield trial in which 43 named varieties and numbered selections of potatoes were compared was conducted during the 1991 growing season at the University of Alaska Fairbanks, Agricultural and Forestry Experiment Station’s Palmer Research Center, Matanuska Research Farm, located six miles west of Palmer, Alaska. Varieties with a history of commercial production in the Matanuska Valley (Alaska 114, Bake-King, Green Mountain, and Superior) are included and serve as a comparative base for newly developed varieties, numbered selections or older varieties that have not been tested at this location. Varieties that compare favorably with the above listed standards may warrant consideration by commercial growers. Nonirrigated trials have been conducted annually since 1982, whereas irrigated trials were initiated in 1985 (AFES Circulars 49, 54, 58, 65, 71, 77, and 84). These circulars are available at the AFES Offices in Fairbanks and Palmer. Included in this report are the results of abbreviated versions of the AFES potato yield trial conducted by cooperating individuals and agencies at other locations in Alaska including Delta Junction, Fairbanks, Homer, Kenai- Soldotna, and Kodiak.[Part 1: Potato Variety Performance] -- Introduction -- Matanuska Farm Yield Trials -- Trials at Other Locations in Alaska -- [Part 2: Commercial Potato Crop Data Summary] -- Introduction -- Potato Varieties and Yields -- Acreage per grower -- Irrigation -- Seed and Planting -- Fertilizer -- Other Cultural Practices -- Chemical Contro

    AFES Circular 80

    Get PDF
    To remain competitive, commercial vegetable producers require updated information on the performance of new vegetable varieties under the soil and climatic conditions of southcentral Alaska. Variety trials provide the opportunity to evaluate potentially adapted plant material. Although many varieties are developed in environments considerably different from that of southcentral Alaska, some may prove to be useful to commercial growers in Alaska. The information on new varieties must be collected over several growing seasons to provide sufficient confidence in the observed performance. Additionally, each year of the performance trials, new varieties are grown with traditional or standard varieties which are used to compare the quality of the new varieties. Commercial production of new varieties should be considered after several years of variety trial work with initial plantings on a small production scale.Introduction -- Overview -- Seed Source List -- Weather Summary -- Broccoli -- Cabbage -- Carrots -- Lettuce -- Potatoe

    The Role of Probiotics in Acne and Rosacea

    Get PDF
    Through basic science as well as animal and human clinical trials, the evidence is growing for the use of probiotics in the treatment of acne. Acne formation is dependent upon several processes, including follicular hyperkeratinization, excess sebum production, Propionibacterium acnes colonization and an inflammatory cascade. The antimicrobial properties of probiotics as well as the modification of the skin microbiome may decrease levels of P. acnes on the skin. Additionally, successful acne outcomes are influenced by compliance with topical regimens, which can commonly cause skin barrier disruption, leading to dryness and irritation. Consequently, calming inflammation as well as maintaining skin hydration and barrier repair is of primary importance when treating acne. In this chapter, we discuss how probiotics affect several factors in the pathophysiology of acne development and can improve the treatment outcomes

    Trans-Ethnic Mapping of BANK1 Identifies Two Independent SLE-Risk Linkage Groups Enriched for Co-Transcriptional Splicing Marks

    Get PDF
    BANK1 is a susceptibility gene for several systemic autoimmune diseases in several populations. Using the genome-wide association study (GWAS) data from Europeans (EUR) and African Americans (AA), we performed an extensive fine mapping of ankyrin repeats 1 (BANK1). To increase the SNP density, we used imputation followed by univariate and conditional analysis, combinedwith a haplotypic and expression quantitative trait locus (eQTL) analysis. The data from Europeans showed that the associated region was restricted to a minimal and dependent set of SNPs covering introns two and three, and exon two. In AA, the signal found in the Europeans was split into two independent effects. All of the major risk associated SNPs were eQTLs, and the risks were associated with an increased BANK1 gene expression. Functional annotation analysis revealed the enrichment of repressive B cell epigenomicmarks (EZH2 and H3K27me3) and a strong enrichment of splice junctions. Furthermore, one eQTL located in intron two, rs13106926, was found within the binding site for RUNX3, a transcriptional activator. These results connect the local genome topography, chromatin structure, and the regulatory landscape of BANK1 with co-transcriptional splicing of exon two. Our data defines a minimal set of risk associated eQTLs predicted to be involved in the expression of BANK1 modulated through epigenetic regulation and splicing. These findings allow us to suggest that the increased expression of BANK1 will have an impact on B-cell mediated disease pathways.The work presented in this paper has been supported by the Ministerio de EconomĂ­a y Competitividad, Spain (SAF2016-78631-P), partly co-financed by FEDER funds of the European Union, the Gustaf den V:e-80-ĂĄrs Fond and the Swedish Association against Rheumatism to M.E.A-R. In addition, this work was financed by the NIH P01 grant P01-AI-083194 to C.D.L., J.B.H., R.K., and M.E.A-R. JBH: NIH grants: R01 AI024717, U01 HG00866, P30 AR070549 and U01 AI130830 and the US Department of Veterans Affairs: I01 BX001834.C.D.L.: Center for Public Health Genomics. R.K.: NIH grant R01-AR33062. J.A.J.: NIH grants U54GM104938, P30AR053483
    • …
    corecore